PNT Pharma Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: PNT Pharma Pharmaceutical Export Portfolio Dataset — 2 Products, $389.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

PNT Pharma — Pharmaceutical Exporter Profile (2026) | 2 Products, $389.8K Trade | TransData Nexus

PNT Pharma

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $389.8K Total Trade · DGFT Verified

PNT Pharma is an Indian pharmaceutical exporter with a total trade value of $389.8K across 2 products in 1 therapeutic categories. Based on 32 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Trastuzumab ($303.1K), Rituximab ($86.7K), .

PNT Pharma — Export Portfolio & Destination Treemap

PNT Pharma pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is PNT Pharma? — Company Overview & Market Position

PNT Pharma is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established approximately 15 years ago, the company has experienced significant growth in the global pharmaceutical market. The company's registered office is located at D Wing, 2nd Floor, 206 Neelkanth Business Park, near Vidyavihar Bus Depot, Vidyavihar (W), Mumbai 400086, India.

PNT Pharma's product portfolio is concentrated in the oncology therapeutic category, with a focus on advanced oncology treatments. The company's total export value stands at $390,000 USD, with 32 shipments across two products. The top two products are Trastuzumab, accounting for $303,000 USD (Rank #13, 0.4% market share), and Rituximab, contributing $87,000 USD (Rank #11, 0.5% market share). This indicates a high portfolio concentration, with the top five products comprising 100% of the company's exports.

What Does PNT Pharma Export? — Product Portfolio Analysis

Top Products by Export Value

1Trastuzumab$303.1K 2

Product Portfolio — Top 2 by Export Value

PNT Pharma exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Trastuzumab	Advanced Oncology	$303.1K	20	0.4%	13
2	Rituximab	Advanced Oncology	$86.7K	12	0.5%	11

PNT Pharma exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $389.8K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

PNT Pharma — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding PNT Pharma's manufacturing facilities, including their locations, capacities, and specializations, are not publicly disclosed. The company's website does not provide this information, and no additional sources are available to confirm these details.

3Key Leadership

PNT Pharma's leadership team includes:

Director: Shivam Tiwari (Jeetu)
Head of Export: Ajay Dubey
Chief Executive Officer (CEO): Chhaya Tiwari
Chief Pharmacist: Chandan Rajbhar

These individuals play pivotal roles in steering the company's strategic direction and operations. Their contact information is available on the company's official website.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does PNT Pharma Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

PNT Pharma's presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan is not explicitly detailed in the available sources. The company's export data indicates shipments to various countries, but specific regulatory approvals or market access statuses in these regions are not provided. Without explicit information on regulatory filings, approvals, or market access statuses, a comprehensive analysis of PNT Pharma's standing in these markets cannot be conducted.

2Emerging Markets

PNT Pharma has expanded its reach to over 20 countries, including regions in Africa, Latin America, and Southeast Asia. The company's export destinations encompass Ethiopia, Kenya, Rwanda, Nigeria, Zambia, Egypt, Turkey, Russia, Uzbekistan, Kyrgyzstan, Kazakhstan, Dubai, Saudi Arabia, Qatar, the Philippines, Tanzania, China, Hong Kong, Malaysia, and Afghanistan.

While the company's website does not specify WHO prequalification status, its extensive export footprint suggests a strategic focus on emerging markets. However, without explicit information on WHO prequalification or other regulatory certifications, a detailed assessment of PNT Pharma's compliance with international standards in these markets cannot be provided.

3Geographic Strategy

PNT Pharma — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding PNT Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history is not publicly available. The company's website does not provide these details, and no additional sources are accessible to confirm FDA-related information. Without explicit data, a comprehensive assessment of PNT Pharma's FDA status cannot be conducted.

2WHO & EU GMP

The available sources do not provide information on PNT Pharma's WHO prequalification status, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The company's website does not disclose these certifications, and no additional sources are available to confirm compliance with these international standards. Without explicit information, a detailed analysis of PNT Pharma's adherence to WHO and EU GMP standards cannot be performed.

3CDSCO & Indian Regulatory

PNT Pharma — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

PNT Pharma operates in the oncology segment, exporting finished pharmaceutical formulations such as Trastuzumab and Rituximab. The company's top two products have market shares of 0.4% and 0.5%, respectively, indicating a presence in a competitive market. However, specific information regarding direct competitors, their market shares, and a head-to-head analysis is not available in the provided sources. Without explicit data, a detailed competitive landscape assessment cannot be conducted.

2Key Differentiators

PNT Pharma's key differentiators include its specialization in oncology medicines and its extensive export network spanning over 20 countries. The company's focus on advanced oncology treatments positions it in a niche market segment. However, the high portfolio concentration, with the top five products comprising 100% of exports, may limit diversification. Without explicit information on unique strengths or competitive advantages, a comprehensive analysis cannot be performed.

3Strategic Position

PNT Pharma's strategic direction appears to be focused on exporting finished pharmaceutical formulations, particularly in the oncology segment. The company's extensive export network suggests a proactive approach to market expansion. However, the high portfolio concentration indicates potential risks associated with over-reliance on specific products. Without explicit information on future outlooks or strategic plans, a detailed assessment cannot be conducted.

Buyer Due Diligence Brief — Evaluating PNT Pharma as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

PNT Pharma's track record in terms of export volume and consistency is indicated by its total export value of $390,000 USD across 32 shipments. The company's focus on oncology medicines suggests a specialization in this therapeutic area. However, without explicit information on reliability indicators or consistency in supply, a comprehensive assessment cannot be performed.

2Certifications to Verify

Importers should verify the following certifications when considering PNT Pharma as a supplier:

FDA Facility Registration: To confirm compliance with U.S. regulatory standards.
WHO-GMP Certification: To ensure adherence to international manufacturing practices.
EU GMP Certification: To verify compliance with European manufacturing standards.
ISO Certification: To assess the company's quality management systems.

Frequently Asked Questions — PNT Pharma

How many pharmaceutical products does PNT Pharma export from India?

PNT Pharma exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Trastuzumab ($303.1K), Rituximab ($86.7K). Total export value is $389.8K.

What is PNT Pharma's total pharmaceutical export value?

PNT Pharma's total pharmaceutical export value is $389.8K, based on 32 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does PNT Pharma cover?

PNT Pharma exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 2 products).

Get Full PNT Pharma Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.